Anti-LPA antibody: Phase Ia data

Top-line data from a double-blind, placebo-controlled, U.S. Phase Ia trial in 36 healthy volunteers showed that single doses of 0.5, 1, 3, 10 and 20 mg/kg IV Lpathomab were well tolerated with no seri...